HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications

P. Tarantino, S. L. Niman,T. Erick,N. Priedigkeit,B. Harrison, A. Giordano,F. Nakhlis,J. R. Bellon,T. Parker,S. Strauss,Q. Jin,T. A. King,B. Overmoyer,G. Curigliano,M. Regan,S. Tolaney,F. Lynce

ANNALS OF ONCOLOGY（2022）

引用 12|浏览3

暂无评分

摘要

•Trastuzumab deruxtecan showed to prolong survival in HER2-low breast cancer (BC).•No data exist on the clinical role of HER2-low expression in inflammatory BC (IBC).•We found more ER-expressing tumours among stage III HER2-low (versus HER2-zero) IBC.•As in non-IBC, no clear prognostic role emerged for HER2-low expression in IBC.•Our results do not support HER2-low as a distinct subtype of IBC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要